MedTrace Logo

Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

NCT01072591 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2013-01-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MEDI-578, a monoclonal antibody, in patients with osteoarthritis of the knee. It will also be evaluated how MEDI-578 is absorbed and distributed through the body.

Conditions

Interventions

DRUG

MEDI-578

intravenous infusion, once

DRUG

Placebo for MEDI-578

Intravenous infusion, once

Sponsors & Collaborators

  • MedImmune LLC

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Rolf Karlsten · AstraZeneca RD Södertälje

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United Kingdom

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01072591 on ClinicalTrials.gov